(S)-4-异丁基-2-噁唑烷酮 | 17016-85-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 中文名称: (S)-4-异丁基-2-噁唑烷酮
• 英文名称: (S)-4-isobutyloxazolidin-2-one
• 英文别名: (4S)-4-(2-methylpropyl)-1,3-oxazolidin-2-one
• CAS: 17016-85-2
• 化学式: C₇H₁₃NO₂
• 分子量: 143.186
• InChiKey: QQOAHLJDKWZJPD-LURJTMIESA-N

物化性质

• 沸点：
  300.9±9.0 °C(Predicted)
• 密度：
  0.999±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090
• 储存条件：
  室温

SDS

Name:	(4S)-4-Isobutyl-2-oxazolidinone Material Safety Data Sheet
Synonym:
CAS:	17016-85-2

Section 1 - Chemical Product MSDS Name:(4S)-4-Isobutyl-2-oxazolidinone Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
17016-85-2	(4S)-4-Isobutyl-2-oxazolidinone		unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 17016-85-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: white to light yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H13NO2
Molecular Weight: 143.19

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 17016-85-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(4S)-4-Isobutyl-2-oxazolidinone - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 17016-85-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 17016-85-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 17016-85-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (S)-4-异丁基-2-噁唑烷酮 在 三乙烯二胺 、 正丁基锂 、 四氯化钛 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 (2S,3S)-1,4-bis[(4S)-4-(2-methylpropyl)-2-oxo-1,3-oxazolidin-3-yl]-2,3-diphenylbutane-1,4-dione
  参考文献：
  名称：

  通过手性3-（芳基乙酰基）-2-恶唑烷酮的氧化均偶联反应不对称合成旋光的2,3-二芳基琥珀酸

  摘要：

  通过用DABCO-TiCl 4或DMAP-TiCl 4处理，实现手性3-（芳基乙酰基）-2-恶唑烷酮1的氧化均偶联，并立体定向提供相应的二聚体。（4S）-和（4R）-取代的1的反应得到（S，S）-和（R，R）-二聚体。获得的二聚体容易转化为相应的2，3-二芳基琥珀酸。因此，该反应提供了用于合成光学纯的2，3-二芳基琥珀酸的有用方法。芳基上的给电子基团的对位取代不会抑制氧化偶合。然而，对位取代的吸电子基团和邻位取代基阻碍了偶联。

  DOI：

  10.1016/s0040-4020(98)83006-8
• 作为产物：
  描述：

  N-苄氧羰基-L-亮氨酸 在 硫酸 、 palladium on activated charcoal 、 氢气 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 (S)-4-异丁基-2-噁唑烷酮
  参考文献：
  名称：

  Discovery of (S)-4-isobutyloxazolidin-2-one as a novel leucyl-tRNA synthetase (LRS)-targeted mTORC1 inhibitor

  摘要：

  A series of leucinol analogs were investigated as leucyl-tRNA synthetase-targeted mTORC1 inhibitors. Among them, compound 5, (S)-4-isobutyloxazolidin-2-one, showed the most potent inhibition on the mTORC1 pathway in a concentration-dependent manner. Compound 5 inhibited downstream phosphorylation of mTORC1 by blocking leucine-sensing ability of LRS, without affecting the catalytic activity of LRS. In addition, compound 5 exhibited cytotoxicity against rapamycin-resistant colon cancer cells, suggesting that LRS has the potential to serve as a novel therapeutic target. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2016.05.011

文献信息

• Synthesis of Oxazolidinone and Tosyl Enamines by Tertiary Amine Catalysis
  作者：Gabriel Fenteany、Nicholas Eddy、Peter Morse、Martha Morton

  DOI：10.1055/s-0030-1259561

  日期：2011.3

  procedure for the synthesis of oxazolidinone and tosyl enamines is reported. Alkynoyl oxazolidinones and tosyl imides undergo reaction to form enamines in the presence of catalytic amounts of tertiary amines. The data suggest that an amide anion is formed during the reaction, which undergoes conjugate addition to form the final product.

  报道了合成恶唑烷酮和甲苯磺胺的方法。炔酰基恶唑烷酮和甲苯磺酰亚胺在催化量的叔胺存在下反应形成烯胺。数据表明在反应过程中形成了酰胺阴离子，其经历共轭加成以形成最终产物。
• Asymmetric Synthesis of Aminocyclopropanes and<i>N</i>-Cyclopropylamino Alcohols Through Direct Amidocyclopropanation of Alkenes Using Chiral Organozinc Carbenoids
  作者：Guillaume Bégis、David E. Cladingboel、Laure Jerome、William B. Motherwell、Tom D. Sheppard

  DOI：10.1002/ejoc.200801033

  日期：2009.4

  Chiral N-(diethoxymethyl)oxazolidinones, prepared from the corresponding oxazolidinones by heating in triethyl orthoformate can he used as organozinc carbenoid precursors for the direct enantioselective amidocyclopropanation of alkenes. The reaction is successful with it wide range of oxazolidinones and alkenes and proceeds with moderate to excellent, yield and stereoselectivity. In most cases the

  通过在原甲酸三乙酯中加热由相应的恶唑烷酮制备的手性 N-(二乙氧基甲基)恶唑烷酮可用作烯烃的直接对映选择性酰氨基环丙烷化的有机锌卡宾前体。该反应在广泛的恶唑烷酮和烯烃下成功，并以中等至极好的收率和立体选择性进行。在大多数情况下，反式/外置酰氨基-环丙烷产物是有利的，尽管某些环状烯烃如茚有利于内环丙烷的形成。这些产品可以很容易地加工成环丙氨基醇和氨基酸。((C) Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2009)
• Visible‐Light‐Mediated Liberation and In Situ Conversion of Fluorophosgene
  作者：Daniel Petzold、Philipp Nitschke、Fabian Brandl、Veronica Scheidler、Bernhard Dick、Ruth M. Gschwind、Burkhard König

  DOI：10.1002/chem.201804603

  日期：2019.1.2

  to its fragmentation into fluorophosgene and benzonitrile. The in situ generated fluorophosgene was used for the preparation of carbonates, carbamates, and urea derivatives in moderate to excellent yields via an intramolecular cyclization reaction. Transient spectroscopic investigations suggest the formation of a catalyst charge‐transfer complex‐dimer as the catalytic active species. Fluorophosgene

  报道了不基于自由基反应性的光催化产生高度亲电中间体的第一个实例。有机光敏剂对稳定的和市售的4-（三氟甲氧基）苄腈进行单电子还原会导致其分裂为氟光气和苄腈。原位产生的氟光气用于通过分子内环化反应以中等至极好的收率制备碳酸盐，氨基甲酸酯和尿素衍生物。瞬态光谱研究表明，形成了一种催化剂电荷转移复合物-二聚体，作为催化活性物质。氟光气作为高反应性中间体，通过NMR间接检测到它的下一个下游碳酰氟中间体。此外，
• 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH
  申请人：VESTAS WIND SYSTEMS A/S

  公开号：US20140235620A1

  公开（公告）日：2014-08-21

  The invention is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 1 -R 6 are defined herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  该发明涉及公式（I）的化合物或其药用盐，其中R1-R6在此处定义。该发明还涉及含有公式（I）化合物的组合物，以及利用这些化合物抑制具有新型活性的突变IDH蛋白。该发明还涉及利用公式（I）的化合物治疗与这些突变IDH蛋白相关的疾病或紊乱，包括但不限于细胞增殖紊乱，如癌症。
• INHIBITORS OF CAMKK2 AND USES OF SAME
  申请人：New York University

  公开号：US20200369656A1

  公开（公告）日：2020-11-26

  The present disclosure provides compounds suitable for inhibiting CaMKK2. Also provided are compositions and methods of treating diseases associated with CaMKK2.

  本公开提供适用于抑制CaMKK2的化合物。还提供了与CaMKK2相关疾病的治疗方法和组合物。